Watch stocks you care about
Your own personalized stock watchlist!
It's a 100% FREE Motley Fool service...
Amarin (NASDAQ: AMRN ) has been a roller coaster of a stock since the launch of its fish oil drug Vascepa. The drug competes with GlaxoSmithKline's fish oil Lovaza, but while Glaxo's drug is often used off label in patients with moderately high triglyceride levels, Amarin hasn't made much in roads into that population.
To get the drug approved for the expanded indication, the biotech signed a special protocol assessment with the Food and Drug Administration, agreeing to run an efficacy study with a surrogate endpoint -- lowering triglyceride levels -- and to substantially enroll an outcomes study measuring cardiac events, such as heart attacks and strokes.
Despite Amarin living up to its end of the bargain -- Vascepa looked even better that GlaxoSmithKline's Lovaza in terms of triglyceride and cholesterol levels -- the FDA decided it really wanted to see the outcomes data, citing data from trials testing Merck's (NYSE: MRK ) Cordaptive and AbbVie's Tricor, triglyceride-lowering drugs that work under a different mechanism of action. Both Merck's and AbbVie's drugs lowered triglyceride levels, but failed to improve outcomes.
In the video that follows, Max Macaluso, the Fool's health care bureau chief, and Fool contributor Brian Orelli discuss the biotech's latest predicament.
A company set up for a solid 2014
The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.